Citi rates ResMed Inc (RMD) as a Buy - The broker notes that although the shares have struggled hard on the resurfacing of competitive bidding concerns, the...

Livewire News

Citi rates ResMed Inc (RMD) as a Buy - The broker notes that although the shares have struggled hard on the resurfacing of competitive bidding concerns, the reaction is largely overdone and current levels are presenting a great buying opportunity. Citi believes the current situation will also offer a valuable opportunity for the company to return excess capital via the current buyback, which is already highly EPS and value-accretive. The price target is $5.79 (current price $4.82) with FY14 PER looking cheap at 15x. However, Citi notes significant upside risk to its forecasts if falls in the AUD continue.


Comments

Please sign in to comment on this wire.